Announcements
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
More ▼
Key statistics
As of last trade, Organovo Holdings Inc (4OR1:FRA) traded at 0.883, 11.21% above the 52 week low of 0.794 set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.883 |
---|---|
High | 0.883 |
Low | 0.883 |
Bid | 0.914 |
Offer | 0.973 |
Previous close | 0.893 |
Average volume | 3.22k |
---|---|
Shares outstanding | 10.04m |
Free float | 9.85m |
P/E (TTM) | -- |
Market cap | 9.92m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:13 BST.
More ▼